Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

AEterna Zentaris Inc T.AEZ

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  AEZS

AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology.
Price: $0.60 Volume: 62,457
Change: $0.00 % Change: 0.00%
Day High/Low: 0.60/0.57 52 Week High/Low: 1.71/0.55
Last Traded: November 26, 2014 10:56 Transaction Volume: 100
Open: 0.58 Previous Close: 0.60
Bid: 0.57 Ask: 0.60
Bid Size: 5500 Ask Size: 500
Market Cap: 39.3m Shares Out: 65.5m
PE Ratio: N/A Dividend Yield: N/A

Latest Bullboard Posts

  • RE:RE:RE:RE:Resume trading

    0 stars

    they might do another reverse split to keep their naz listing...their horn of aplenty...never ending funding up to now has always been...

    4.5 stars


  • RE:RE:RE:RE:Resume trading

    0 stars

    The biggest risk is how will Ascend respond to the FDA rejection. They were suppose to co-promote both drugs. Lawsuit won't help either...

    2.5 stars


  • RE:RE:RE:Resume trading

    0 stars

    I'm gonna hold....lots of risk though, they've got a nice pipeline but the FDA ruling doesn't help investor confidence for their other...

    2 stars


  • RE:RE:Resume trading

    0 stars

    That press release was from 2011...obviously a lot has happened since. Still mangement should not have been blindsided by the ruling

    2.5 stars


  • RE:Resume trading

    0 stars

    They were not concerns......................it was a total rejection of the clinical results. We were told that Phase 3 endpoints were...

    2.5 stars